EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study

Yongjian Zhou, Chunling Zeng, Xiaofeng Sun, Jun Zhang, Hongyan Qu, Xinhua Zhang, Ye Zhou, Zimin Liu, Xiaojun Wu, Xin Wu, Xuelong Jiao, Lin Shen und 3 weitere

The Oncologist · 06.04.2023 · 28 (4) · e191-e197

DOI: 10.1093/oncolo/oyac271 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 13.02.2023. Verfasst von Yongjian Zhou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, People's Republic of China. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anlotinib is a multi-target tyrosine kinase inhibitor that can effectively inhibit tumor cell proliferation after receptor kinase activation caused by KIT gene mutation.

Methods

We tested the inhibitory effect of anlotinib in GIST cell lines with different gene mutations and evaluated the efficacy of anlotinib for patients with metastatic GIST after imatinib failure in a multicenter, single-arm, phase II study.

Results

In vitro, V654A mutation encoded by KIT exon 13 was intermediately sensitive to anlotinib. Moreover, anlotinib was able to partly suppress the activation loop mutation D820A from exon 17 while another activation loop mutation N822K, also from exon 17, was resistant to anlotinib. From September 2018 to October 2020, 64 patients from 9 Chinese medical centers were enrolled in this study. Seven patients had partial response and 39 patients had stable disease. The median PFS was 8.0 months. There was no statistical significance comparing with PFS of sunitinib second-line therapy at the same period. The most common adverse events related to anlotinib treatment were hypertension, neutropenia, and fatigue.

Conclusion

Anlotinib showed moderate antitumor activity in drug-resistant GIST cell lines in vitro, and good PFS and better tolerance in second-line therapy study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsAntineoplastic AgentsHumansProspective StudiesSunitinibMutationProto-Oncogene Proteins c-kitDrug Resistance, NeoplasmIndolesQuinolines

Stichwörter der Autor:innen

anlotinibantitumor activitygastrointestinal stromal tumorsecond-line treatment

Substanzen

Antineoplastic AgentsSunitinibProto-Oncogene Proteins c-kitanlotinibIndolesQuinolines

Autor:innen und Institutionen

  • Department of Gastric Surgery, Fujian Medical University Union Hospital, Fujian, People's Republic of China.
  • CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, People's Republic of China.
  • Department of Internal Medicine, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & the Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu, People's Republic of China.
  • Department of Gastrointestinal Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
  • The Second Ward of Gastroenterology Department, Harbin Medical University Cancer Hospital, Heilongjiang, People's Republic of China.
  • Department of Gastrointestinal Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangdong, People's Republic of China.

ORCID-Profile: Yuexiang Wang

Förderung

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Zitieren

APA

Zhou, Y., Zeng, C., Sun, X., Zhang, J., Qu, H., Zhang, X., Zhou, Y., Liu, Z., Wu, X., Wu, X., Jiao, X., Shen, L., Zhou, Y., Wang, Y., & Li, J. (2023). Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. The Oncologist, 28(4), e191-e197. https://doi.org/10.1093/oncolo/oyac271

Vancouver

Zhou Y, Zeng C, Sun X, Zhang J, Qu H, Zhang X, et al. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study. The Oncologist. 2023;28(4):e191-e197. doi:10.1093/oncolo/oyac271

BibTeX
@article{Zhou2023,
  author = {Zhou, Yongjian and Zeng, Chunling and Sun, Xiaofeng and Zhang, Jun and Qu, Hongyan and Zhang, Xinhua and Zhou, Ye and Liu, Zimin and Wu, Xiaojun and Wu, Xin and Jiao, Xuelong and Shen, Lin and Zhou, Yanbing and Wang, Yuexiang and Li, Jian},
  title = {Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {4},
  pages = {e191--e197},
  doi = {10.1093/oncolo/oyac271}
}
Kostenlos starten →